Clinical Trials
15
Active:2
Completed:6
Trial Phases
4 Phases
Phase 1:8
Phase 2:3
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)β’ Click on a phase to view related trials
Phase 1
8 (53.3%)Not Applicable
3 (20.0%)Phase 2
3 (20.0%)Phase 3
1 (6.7%)A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
Not Applicable
Not yet recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: The high-dose group of ZL-82 tabletsDrug: The low-dose group of ZL-82 tabletsDrug: The placebo group
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 111
- Registration Number
- NCT07193589
- Locations
- π¨π³
West China Hospital Sichuan University, Chengdu, Sichuan, China
A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets
Not Applicable
Completed
- Conditions
- Heathly Subjects
- Interventions
- Drug: flunotinib
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT07193576
- Locations
- π¨π³
Chengdu Xinhua Hospital, Chengdu, Sichuan, China
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Phase 3
Recruiting
- Conditions
- Recurrent and Refractory Diffuse Large B-cell Lymphoma
- Interventions
- Drug: Selinexor TabletsDrug: Purinostat Mesylate for Injection
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 390
- Registration Number
- NCT07011056
- Locations
- π¨π³
West China Hospital Sichuan University, Chengdu, Sichuan, China
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions
- Drug: Purinostat Mesylate 4 mg/m2Drug: Purinostat Mesylate 6 mg/m2Drug: Purinostat Mesylate 8.4 mg/m2
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 144
- Registration Number
- NCT06484829
- Locations
- π¨π³
West China Hospital Sichuan University, Chengdu, Sichuan, China
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Cutaneous T-cell Lymphoma (CTCL)Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Interventions
- Drug: 11.2 mg/m2 Purinostat MesylateDrug: 15 mg/m2 Purinostat Mesylate
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT06485219
- Locations
- π¨π³
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, Shanghai, China
π¨π³West China Hospital Sichuan University, Chengdu, Sichuan, China
- Prev
- 1
- 2
- 3
- Next
News
No news found